Bipolar Sealer for Reduction of Blood Loss in Anterior Total Hip Arthroplasties

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-29

Study Completion Date

2024-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objectives and purpose of this study is to show that the Smith and Nephew Werewolf Fastseal 6.0 Bipolar Sealer is an effective tool to aide the surgical team in providing significant hemostasis during anterior total hip arthroplasty which would subsequently improve patient outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reduced Total Blood Loss and Blood Transfusion in Non-Septic Revision Knee Arthroplasty Using a Bipolar Sealer

NCT02427711

Total Blood Loss

COMPLETED NA

Cell Saver Use in Bilateral Total Hip Arthroplasty (THA)

NCT01468129

One-stage Bilateral Total Hip Replacement

UNKNOWN NA

The Use of Barbed Sutures in Total Hip Arthroplasty

NCT02609464

Osteoarthritis, Hip

COMPLETED NA

A Clinical Investigation of the Taperloc® Microplasty™ Hip System

NCT00699309

Osteoarthritis Rheumatoid Arthritis Avascular Necrosis

COMPLETED

An MRI Investigation of Soft Tissues in Total Hip Arthroplasty

NCT01750606

Tissue Reaction Elevated Blood Ion Levels

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis, Hip Blood Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group Receiving Fastseal

Group Type OTHER

Werewolf Fastseal 6.0

Intervention Type DEVICE

bi-polar hemostatic wand

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Werewolf Fastseal 6.0

bi-polar hemostatic wand

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient is to undergo a standard of care primary total hip replacement for degenerative joint disease. All devices are to be used according to the approved indications, this includes the FDA approved Werewolf Fastseal Bipolar Device.
* The patient is expected to have an outpatient status and will be discharged \<23 hours.
* Individuals who are able to speak, read, and comprehend the Institutional Review Board approved Informed Consent Document and willing and able to provide informed patient consent for participation in the study.
* Individuals who are willing and able to complete follow-up visits and questionnaires as specified by the study protocol.
* Individuals who are not bedridden per the discretion of the investigator (The intent of "not bedridden" means a permanent situation, not a temporary situation as in a hip fracture or trauma case).
* Individuals who are a minimum age of 21 years and less than 80 years at the time of consent.

Exclusion Criteria

* Active local or systemic infection.
* Hematologic disease either inherited or acquired, that would predispose the patient to anemia or increased intra-operative blood loss
* Currently taking anti-coagulation medications more than 81 mg aspirin every day.
* Platelet disorder either inherited or acquired with a serum platelet level \<150,000 platelets per microliter.
* Coagulopathy as seen with routine lab work
* Unstable/uncontrolled cardiovascular disease such as congestive heart failure, hypertension, or renal disease such as GFR \<70, in the opinion of the investigative team and PI.
* Excessive alcohol intake or tobacco use, in the opinion of the investigator.
* Uncontrolled diabetes mellitus with hemoglobin a1c \>7.5%.
* Established history of previous venous thrombotic events (VTE).
* Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified.
* The subject is a woman who is pregnant or lactating.
* Subject had a contralateral amputation.
* Previous partial hip replacement in affected hip.
* Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three months.
* Contralateral hip was replaced less than 3 months prior to surgery date, contralateral hip is already enrolled in the study, or simultaneous or staged hip replacement is planned
* Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
* Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.
* Subject, in the opinion of the Investigator, is a drug or alcohol abuser or has a physical or psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No